New research indicates that patients who come off popular slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop conventional lifestyle programs.
Research printed in a leading medical journal points out that while overweight individuals can lose about a fifth of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People using such drugs need to be aware of the danger of rapid rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment weight within about 18 months.
Comparing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the effects of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through lifestyle changes alone typically experience a slower creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Nutrition scientists propose the way of the injections is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating a significant risk."
An Ongoing Disease?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, due to the significant potential of relapse, the therapy is often ongoing.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the chronic nature of excess weight," akin to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the jabs report a sudden return of cravings.
"It was like a trigger flipping and I was suddenly extremely hungry," described an individual.
This challenge is worsened if users have not developed permanent lifestyle or habit changes during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle changes.
